{"id":"W2903904475","doi":"10.1093/annonc/mdy415","title":"Alectinib as first-line therapy for ALK-rearranged NSCLC: a no-brainer?","year":2018,"lang":"en","type":"letter","venue":"Annals of Oncology","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":true,"ca_institutions":"","funders":"Bristol-Myers Squibb Canada; Merck; AstraZeneca","keywords":"Alectinib; Medicine; Crizotinib; Oncology; First line therapy; Internal medicine; Lung cancer","routes":{"ca_aff":false,"ca_fund":true,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":true},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.002010887,0.000342708,0.001479839,0.0008589833,0.0003709076,0.002474995,0.0008837782,0.001771885,0.009841098],"category_scores_gemma":[0.005253608,0.0001412436,0.0008407155,0.0009753862,0.000777947,0.003665103,0.0008716413,0.003250731,0.004727036],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.001008607,"about_ca_system_score_gemma":0.001462407,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.001049493,"about_ca_topic_score_gemma":0.005799798,"domain_scores_codex":[0.9990375,0.0003827235,0.0001198082,0.00009437485,0.0002630835,0.0001025671],"domain_scores_gemma":[0.998189,0.000666166,0.0003995505,0.00006280602,0.0003453327,0.0003370999],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"design_other","study_design_gemma":"not_applicable","study_design_scores_codex":[0.003129443,0.0001618713,0.001468702,0.00586894,0.0004331305,0.0007908413,0.0001779314,0.0003235832,0.00148835,0.008632964,0.2260296,0.7514946],"study_design_scores_gemma":[0.001892398,0.001848311,0.005510629,0.01911462,0.001046911,0.003875733,0.0009821674,0.0009500941,0.001215737,0.02450241,0.9389228,0.0001381053],"study_design_candidate":"not_applicable","study_design_consensus":null,"genre_codex":"review","genre_gemma":"commentary","genre_scores_codex":[0.008164247,0.6972557,0.0009107067,0.2709289,0.005548377,0.00003544731,0.0006125024,0.0001300051,0.01641411],"genre_scores_gemma":[0.150798,0.7011028,0.002425806,0.1141167,0.01258104,0.00008819607,0.0009430801,0.0001990568,0.01774536],"genre_candidate":"commentary","genre_consensus":null,"teacher_disagreement_score":0.009841098,"threshold_uncertainty_score":0.03292173,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.1069926659110964,"score_gpt":0.4628576205310257,"score_spread":0.3558649546199293,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}